Novel promising therapeutic agents in multiple sclerosis.
Multiple sclerosis (MS) is the most common chronic demyelinating disease of the central nervous system, which causes progressive neurological disability. Over the recent decade, there has been an impressive accumulation of data about novel designed immunosuppressive and anti-inflammatory agents promising for treating MS and its animal model, experimental autoimmune encephalomyelitis. Regarding, disease-modifying therapies appear to be modest in the magnitude of their treatment effects, particularly in the progressive phase of this disease, novel promising therapeutic strategies could open a light horizon in approaching to an efficient treatment in MS. This review provides a compilation of the more thoroughly studied of these novel immunotherapeutic agents and new aspects of designed molecular targets and patents which have recently evolved.
Mirshafiey
Abbas
A
Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. mirshafiey@tums.ac.ir
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000627:therapeutic use*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010330:Patents as Topic; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D015507:Drugs, Investigational; D007166:Immunosuppressive Agents